# EDGAR Filing Document

**Accession Number:** 0001998781
**File Stem:** 0001493152-26-017941
**Filing Date:** 2026-4
**Character Count:** 19587
**Document Hash:** 6a049848c4daa2d8abb080de42883ea0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-017941.hdr.sgml**: 20260417

**ACCESSION NUMBER**: 0001493152-26-017941

**CONFORMED SUBMISSION TYPE**: 425

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260417

**DATE AS OF CHANGE**: 20260417

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IB Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001998781
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 852946784
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 425
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41988
- **FILM NUMBER:** 26872753

**BUSINESS ADDRESS:**
- **STREET 1:** 2500 N MILITARY TRAIL, SUITE 160-A
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 214-687-0020

**MAIL ADDRESS:**
- **STREET 1:** 2500 N MILITARY TRAIL, SUITE 160-A
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IB Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001998781
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 852946784
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 425

**BUSINESS ADDRESS:**
- **STREET 1:** 2500 N MILITARY TRAIL, SUITE 160-A
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431
- **BUSINESS PHONE:** 214-687-0020

**MAIL ADDRESS:**
- **STREET 1:** 2500 N MILITARY TRAIL, SUITE 160-A
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33431

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **April 15, 2026**

**IB ACQUISITION CORP.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-41988** | **85-2946784** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification Number) |

---

**1200 N Federal Highway, Suite 215**

**Boca Raton, FL 33432**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(214) 687-0020**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common stock, par value US$0.0001 per share | IBAC | The Nasdaq Stock Market LLC |
| Rights, each entitling the holder to receive one-twentieth of one share of common stock | IBACR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events** |

---

**<u>Joint Initiative Marketing Agreement</u>**

On April 15, 2026, GNQ Insilico, Inc. ("GNQ") issued a press release announcing its collaboration with IBM aimed to help healthcare and life science organizations accelerate the adoption of personalized, data-driven medicine. The collaboration is formalized through a global Joint Initiative Marketing Agreement (the "Agreement") with IBM that was signed in March 2026.

The press release is attached hereto as Exhibit 99.1. Notwithstanding the foregoing, information contained on the websites of IB Acquisition, GNQ or any of their affiliates referenced in Exhibit 99.1 or linked therein or otherwise connected thereto does not constitute part of nor is it incorporated by reference into this Current Report on Form 8-K.

**Important Information and Where to Find It**

This Current Report on Form 8-K relates to a proposed transaction between IB Acquisition and GNQ. This Current Report on Form 8-K does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the transaction described herein, IB Acquisition intends to file relevant materials with the United States Securities and Exchange Commission ("<u>SEC</u>"), including a registration statement on Form S-4, which will include a document that serves as a joint prospectus and proxy statement, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all IB Acquisition stockholders. IB Acquisition will also file other documents regarding the proposed transaction with the SEC. **Before making any voting or investment decision, investors and security holders of IB Acquisition are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed transaction as they become available because they will contain important information about the proposed transaction.**

Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by IB Acquisition through the website maintained by the SEC at www.sec.gov.

The documents filed by IB Acquisition with the SEC also may be obtained free of charge upon written request to IB Acquisition Corp., 1200 N Federal Highway, Suite 215, Boca Raton, FL 33432 or via email at ecm@ibsgroup.net.

**Participants in the Solicitation**

IB Acquisition, GNQ and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from IB Acquisition's stockholders in connection with the proposed transaction. A list of the names of such directors and executive officers, and information regarding their interests in the business combination and their ownership of IB Acquisition's securities are, or will be, contained in IB Acquisition's filings with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed transaction may be obtained by reading the proxy statement/prospectus regarding the proposed transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

**Non-Solicitation**

This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of IB Acquisition, or GNQ, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.

**Forward-Looking Statements**

This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed Transaction between IBAC and GNQ. Such forward-looking statements include, but are not limited to, statements regarding the closing of the Transaction and IBAC's, GNQ's, or their respective management teams' expectations, hopes, beliefs, intentions or strategies regarding the future. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intends", "may", "might", "plan", "possible", "potential", "predict", "project", "should", "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to assumptions, risks and uncertainties. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of IBAC and GNQ. Many factors could cause actual future events to differ from the forward-looking statements in this Current Report on Form 8-K, including but not limited to, (i) the risk that the Transaction may not be completed in a timely manner or at all, (ii) the failure to satisfy the conditions to the consummation of the Transaction, including the approval by the stockholders of IBAC, the satisfaction of the minimum trust account amount following any redemptions by IBAC's public stockholders and the receipt of certain governmental and regulatory approvals, (iii) risks related to the timing, outcome and scope of review by the SEC of the registration statement on Form S-4, (iv) the inability to complete the Bridge Financing or PIPE offering, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement, (vi) the outcome of any legal proceedings that may be instituted against IBAC and/or GNQ related to the business combination agreement, (vii) the ability to maintain the listing of IBAC's stock on Nasdaq (or, if applicable, to list and maintain the listing of the combined entity on the NYSE), (viii) volatility in the price of IBAC's securities, (ix) costs related to the Transaction and the failure to realize anticipated benefits of the Transaction, (x) the effect of the announcement or pendency of the Transaction on GNQ's business relationships, operating results, performance and business generally, (xi) risks that the Transaction disrupts current plans and operations of GNQ, (xii) changes in the combined capital structure of IBAC and GNQ following the Transaction, (xiii) changes in the competitive industries and markets in which GNQ operates, (xiv) changes in laws and regulations affecting GNQ's business, (xv) the ability to implement business plans and identify and realize additional opportunities, (xvi) risks related to GNQ's projected financial information and limited operating history, (xvii) risks related to GNQ's potential inability to achieve or maintain profitability and generate cash, (xviii) the enforceability of GNQ's intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (xix) other risks and uncertainties indicated from time to time in the filings of IBAC, including the Form S-4 Registration Statement that IBAC will file. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IBAC and GNQ assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither IBAC nor GNQ gives any assurance that either IBAC or GNQ will achieve its expectations.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release, dated April 15, 2026.](ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **IB ACQUISITION CORP.** | **IB ACQUISITION CORP.** |
| By: | */s/ Al Lopez* |
| Name: | Al Lopez |
| Title: | Chief Executive Officer |

---

Dated: April 17, 2026

## Exhibit 99.1

**Exhibit 99.1**

**GNQ Insilico Plans to Accelerate Precision Medicine and**

**Clinical AI Adoption Across Drug Development and Patient Care**

*The new service offering combines GNQ Insilico's Causal AI Drug Assessment, Drug*

*Simulation, and Digital Twin platforms with IBM's consulting and hybrid cloud expertise.*

SAN JOSE, Calif. — (BUSINESS WIRE) — GNQ Insilico, Inc. (GNQ), a precision medicine TechBio company, today announced a collaboration with IBM aimed to help healthcare and life sciences organizations accelerate the adoption of personalized, data-driven medicine. Through this collaboration, GNQ will deliver its causal AI Drug Assessment, Drug Simulation, and Digital Twin platforms supported by IBM's consulting expertise and hybrid cloud deployment experience. The collaboration is formalized through a global Joint Initiative Marketing Agreement signed in March 2026.

Clinical trial failure rates remain high, and treatment decisions are often made without full insight into individual patient biology. The platforms are designed to address these challenges by pairing GNQ's mechanistic, causal AI models with IBM's secured, scalable technology infrastructure, to support life sciences companies and healthcare providers in their efforts towards more predictive drug development and more personalized clinical decisions.

The platform offerings are now available and are designed to support three primary groups:

● Emerging biopharma companies looking to mitigate risk in early drug development.

● Large pharmaceutical organizations seeking to improve and scale their clinical decision-making.

● Hospitals and health systems aiming to deliver more personalized, data-driven support for treatment decisions.

"GNQ's differentiation is our causal AI framework grounded in elementary reaction kinetics and pathway biology — modeling how therapies interact with individual patient biology at the mechanistic level through quantum-enhanced simulation. Our Biomedical Reasoning Model enables true causal inference, not just pattern recognition. IBM's Consulting's enterprise AI platform, hybrid cloud infrastructure, and deep life sciences industry expertise provide the foundation to deploy this precision medicine platform at scale," said Sudhir Saxena, Chief Technology Officer, GNQ Insilico, Inc. "We believe that AI-driven causal reasoning will define the future of drug development and precision medicine, and we are building that future."

**Combining Causal Reasoning AI with Enterprise Infrastructure**

The offering integrates IBM's consulting and hybrid cloud services with GNQ's digital twin technology, which uses causal simulations and biological pathway modeling to inform how individual patients may respond to therapies. GNQ's platform reasons from the physics of molecules to the fate of patients — encoding biology as quantitative cause-and-effect equations, grounding drug-target interactions in quantum simulation, and providing insights on each patient's individual treatment future through a living causal model of their own biology.

Together, the offering is being designed to help reduce clinical development risk, increase trial success probability, and help clinicians to make more personalized treatment decisions based on mechanistic biological insight.

**Digital Twin Platforms in Action**

The platforms are already generating commercial momentum. GNQ Insilico has signed a three-year, $96 million agreement with a physician-led comprehensive health program operating across North America. Under this agreement, GNQ's Digital Twin Platforms will serve as the foundational clinical AI infrastructure for the program's clinic network, enabling longitudinal, multi-omics-based health insights for physicians and patients.

IBM is supporting GNQ through healthcare and life sciences consulting, hybrid cloud platform deployment, and systems integration for rapid rollout across clinic locations. The collaboration is intended to serve as a model for how combined causal AI and enterprise-grade infrastructure can be deployed across functional medicine networks, provider groups, and health systems globally with the insights from GNQ AI Genomic platforms.

"The life sciences and healthcare industries are at an inflection point. AI is no longer experimental — it is becoming important infrastructure for organizations working to reduce clinical failure rates and move from reactive to more proactive care," said Manoj Kenkare, Senior Partner, Life Sciences Industry Leader, IBM Consulting. "GNQ Insilico brings something differentiated: mechanistic, causal intelligence grounded in pathway biology, rather than pattern matching on historical data. This collaboration brings together capabilities that are truly greater than the sum of their parts, and we see significant potential as we scale this across our global client relationships."

**About GNQ Insilico, Inc.**

GNQ Insilico, Inc. is a California-based precision medicine TechBio company developing quantum-enhanced AI platforms for drug assessment, clinical decision support, and personalized medicine. GNQ's platform stack encompasses the Drug Assessment Platform (DAP), the Drug Simulation Platform (DSP), the Digital Twin Platform (DTP), and the Biomedical Reasoning Model (BRM) — all grounded in causal inference, pathway biology, and quantum molecular simulation.

Website: <u>gnq.ai</u>

 

*Forward-Looking Statements: This press release contains forward-looking statements based on current expectations. Actual results may differ materially. GNQ Insilico assumes no obligation to update these statements. IBM and GNQ Insilico are independent parties. The collaboration described herein does not constitute a legal partnership. Financial transactions for specific engagements are governed by separate agreements between the parties.*

**Contacts**

**Media Contacts**

**GNQ Insilico, Inc.**

Communications & Investor Relations

<u>info@gnq.ai</u>

<u>gnq.ai</u>